Hikma launches Benztropine Mesylate Injection, USP

Product, Press Release

Hikma launches Benztropine Mesylate Injection, USP

London, 24 March 2022 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces it launched Benztropine Mesylate Injection, USP through its US affiliate, Hikma Pharmaceuticals USA Inc. The company has launched 2mg/2mL dose in vial format. Hikma also markets ampoules of this product and this launch broadens the choice of medicines available to hospitals.

Benztropine Mesylate Injection, USP is indicated as an adjunct in the therapy of all forms of parkinsonism.

According to IQVIA, US sales of Benztropine Mesylate Injection, USP, 2mg/2mL, were approximately $5 million in the 12 months ending December 2021.

Hikma is the second largest US supplier of generic injectable medicines by volume, with a growing portfolio of over 120 products. Today one in every six injectable generic medicines used in US hospitals is a Hikma product.